Licensing and R&D opportunities
Blood and cardiovascular disease (4)
Developmental disorders (2)
Infectious disease (3)
Metabolic disease (2)
Page Content Zone 1
Licensing and R&D opportunities
MALT-Paracaspase, a novel therapeutic target in oncology and inflammatory diseases
MALT1 paracaspase inhibition is a novel therapeutic modality in oncology and inflammatory diseases. Screening methods to identify inhibitory compounds are protected.
Method to study protein protein interaction in mammalian cells
A novel screening method for protein-protein interaction in mammalian cells, based on the reconstitution of a membrane receptor
Candida albicans biofilm formation in a rat model
This invention relates to an in vivo model to study Candida biofilm formation on implanted biomaterials. This in vivo rat model can be used to study the inhibitory activity of antimicrobial compounds.
Extracellular targets for Alzheimer's Disease
The inhibition or downregulation of specific tetraspanin proteins can be used as a novel therapeutic approach for Alzheimer’s Disease. As these are extracellular proteins, an antibody-based approach can be anticipated.
Diagnosis, prognosis and theranosis of HIV related
This invention relates to the use of visfatin (mRNA or protein) level in blood samples to diagnose HIV infection, determine the evolution of the disease and to evaluate the efficacy of a treatment.
A CUG codon adapted two-hybrid system for Candida albicans
This invention relates to a two-hybrid system with Candida albicans as the host using components that are compatible for use in this organism.
SIP1, a target to prevent metastasis and a marker for breast cancer aggressiveness
Sip1 is a bio-marker for breast cancer stem cells, which are the cells responsible for tumor extension and metastasis. Sip1 can be used therapeutically to inactivate breast cancer stem cells aimed at lowering morbidity and mortality.
Plasmin therapy to enhance heamatopoetic stem cell mobilization; Plasmin inhibitors to inhibit Leukemogenesis
Plasmin agonists can be used to enhance HSC mobilization to treat leukopenia and neutropenia. Plasmin antagonists can be used to inhibit HSC mobilization to assist in treating malignant disorders such as leukemia, lymphoma and myeloma.
Aging markers in Serum - Physiological Age Markers
This biomarker can be used to scientifically prove the effect of cosmetics, food supplements, medicines, dietary compositions and other ingredients on both humans and animals.
Treatment and diagnosis of dementia
Detection of PRGN mutations or decreased PRGN mRNA or protein levels can be used as a diagnostic method for dementia or dementia risk. Increasing the levels of PRGN in patients at risk for dementia promises to be therapeutic.
Diagnosis and Treatment of T-Cell Acute Lymphoblastic Leukemia using MYB
The duplication of MYB, a gene encoding for a transcription factor, can be used in the molecular phenotyping of T-ALL patients. Knock-down of MYB expression or inhibition of MYB can be exploited therapeutically.
Combination therapy of alpha-galactosylceramide and TNF to combat cancer
The synergistic effect of combination therapy with a single dose of α-galactosylceramide and sub-therapeutic levels of TNF can be exploited to safely combat cancer without the typical side effects of TNF treatment.
Novel, non-invasive biomarker for Alzheimer’s disease
Profiles of sugars derived from N-linked glycoproteins from blood serum can be used as biomarkers to diagnose or to monitor the progress of Alzheimer’s disease.
Novel recombinant adenoviral vector
VIB scientists have developed novel recombinant high capacity adenoviral vectors that produce unprecedented, high levels of clotting factors.
Molecular diagnosis of T-ALL leukemia using the NUP-ABL fusion predicts therapeutic success
Molecular diagnosis using FISH or a PCR-based assay detecting the NUP214-ABL1 fusion can be used to predict the success of the tyrosine kinase inhibitor pathway
Page Content Zone 2
Page Content Zone 3
Get VIB business opportunity updates:
Inflammation and immunity
Training and facilities
Int. Ph.D. Program